Graphite Bio KOL Webinar
Following this event, Graphite Bio provided updates across its R&D programs as part of its fourth quarter and fiscal year 2021 financial results announcement on March 21, 2022, including new timing expectations related to its Phase 1/2 CEDAR clinical trial for sickle cell disease. View the current corporate presentation for the latest anticipated milestones across programs.